[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
May 26, 1989


JAMA. 1989;261(20):2952. doi:10.1001/jama.1989.03420200042017

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


In Reply. —  Although it makes no claim to completeness, the Physicians' Desk Reference does serve as a kind of pharmaceutical "who's who." The absence of a Jname, generic or proprietary, among the more than 2000 products in the 1988 edition spawned several explanatory theories.Personally, I thought it was an aversion on the part of American medicine to words that might be even remotely juridical. J is just too prominent in "judge," "jury," and "jurisprudence."Dr Fogel's kind offer to trade drugs for Caribbean real estate might not be necessary. The 1989 Physicians' Desk Reference lists both Janimine and Jevity. This is probably all the J-drugs a country needs, but I suspect we could handle more if our Canadian colleagues would like to trade J-drugs for JDs.